Healthcare Global Enterprises Limited

rs,

htra, India The Manager – Listing BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India Dear Sir/Madam, Subject : Stock Code : BSE –

77%

er of genomic alterations detected in cohort 54 Number of RNA alterations detected in cohort 77% Patients with actionable and prognostic genetic alterations Up to 80% Assigned to approved th

80%

ions detected in cohort 77% Patients with actionable and prognostic genetic alterations Up to 80% Assigned to approved therapies (for specific indications) Up to 25% Change in clinical manage

25%

genetic alterations Up to 80% Assigned to approved therapies (for specific indications) Up to 25% Change in clinical management (for specific indications) *Abstract accepted for ASCO 2023 Poste

21%

V E N U E R E V E N U E - H C G C e n t e r s ( 1 ) R E V E N U E - M i l a n n C e n t e r s ^ +21% 4,417 3,646 +22% 3,488 4,259 158 158 0% Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 A

22%

U E - H C G C e n t e r s ( 1 ) R E V E N U E - M i l a n n C e n t e r s ^ +21% 4,417 3,646 +22% 3,488 4,259 158 158 0% Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 A D J U S T E D E B I

0%

1 ) R E V E N U E - M i l a n n C e n t e r s ^ +21% 4,417 3,646 +22% 3,488 4,259 158 158 0% Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 A D J U S T E D E B I T D A A D J U S T E D E B I

23%

I T A F T E R TA X 2 ( P r e - I N D A S ) P R O F I T A F T E R TA X 2 ( P o s t - I N D A S ) +23% + 27 bps 831 18.5% 18.8% 676 +19% 112 94 +40% 84 60 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4

27 bps

F T E R TA X 2 ( P r e - I N D A S ) P R O F I T A F T E R TA X 2 ( P o s t - I N D A S ) +23% + 27 bps 831 18.5% 18.8% 676 +19% 112 94 +40% 84 60 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY

18.5%

( P r e - I N D A S ) P R O F I T A F T E R TA X 2 ( P o s t - I N D A S ) +23% + 27 bps 831 18.5% 18.8% 676 +19% 112 94 +40% 84 60 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q

18.8%

e - I N D A S ) P R O F I T A F T E R TA X 2 ( P o s t - I N D A S ) +23% + 27 bps 831 18.5% 18.8% 676 +19% 112 94 +40% 84 60 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23

19%

) P R O F I T A F T E R TA X 2 ( P o s t - I N D A S ) +23% + 27 bps 831 18.5% 18.8% 676 +19% 112 94 +40% 84 60 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Q4FY22 Q4FY23 Adjusted EB

“Although the Company believes that such forward‐looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met.”

“No Particulars Capex incurred till 31 st March 2023 Expected Capex for FY24 Total Planned Capex Expected date of Operations 1 2 Ahmedabad – Phase II Whitefield (Extension of Bangalore - COE) 158 10 636 200 852 250 Q1 FY25 Q3 FY25 1.”

Subject

1

Subject

Stock Code : BSE – 539787, NSE – HCG Investor Presentation We wish to inform you that the Board of Directors of the Company, at their meeting held on May 25, 2023, inter alia, has approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2023 (“Financial Results”). In this respect, we enclose herewith the Presentation on the Financial Results of the Company for the quarter and year ended March 31, 2023. Request you to take this on record. Thanking you, For HealthCare Global Enterprises Limited Sunu Manuel Company Secretary & Compliance Officer Encl: a/a. HealthCare Global Enterprises Limited HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027. 080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489 HEALTHCARE GLOBAL ENTERPRISES LIMITED INV E STOR P R E SE NTAT ION May 2023 SAFE HARBOR This presentation and its contents are confidential and are not for release, publ